Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Clinical Trials

Cardiovascular Clinical Trials

New studies are looking at ways to lower the risks of heart disease and stroke from just about every angle. Here are a few examples of the many Cardiovascular Research clinical trials in progress and open for enrollment. For more information call 302-733-2658.


Study title
ZEUS: Testing a new cardiac imaging agent—Open-Label, Phase 2 Study of the Safety and Efficacy of ß-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid I 123) for Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Adults with Symptoms Consistent with Acute Coronary Syndrome (ACS)

Principle investigator
Timothy Manzone, M.D.

Description
An investigational drug (iodofiltic acid I-123) is being tested to help detect heart injury sooner in patients who come to the emergency department with chest pain. Current methods used to evaluate chest pain in the emergency department, including electrocardiograms and blood tests, do not provide enough information quickly to know if there has been any heart injury. Heart pictures taken with iodofiltic acid I-123, using a nuclear medicine technique called single photon emission computed tomography (SPECT), will be compared to the final results of all the patient’s tests to determine if the investigational drug is useful in detecting heart problems sooner than what is currently available.


Study title
Precision Study: Is one type of arthritis drug better for patients with cardiovascular disease?

Principle investigator
Arthur Colbourn, M.D.

Co-investigators
Mark Zolnick, M.D. and Michael Stillabower M.D.

Description
Patients who have coronary heart disease or multiple risk factors are the focus of this worldwide study comparing the safety and efficacy of Celebrex (a COX-2 inhibitor) to Motrin (Ibuprofen) or Aleve (Naproxen), both of which are non-steroidal anti-inflammatory drugs or NSAIDs.. Participants will be randomized to receive one or the other of the study drugs to treat their symptoms of osteoarthritis, the most common form of arthritis. Patients with rheumatoid arthritis will also be included in the study.


Study title
AIM-HIGH Study: Can two drugs work better than one to promote healthy cholesterol?

Principle investigator
Edward Goldenberg, M.D.

Co-investigators
John Kelly, M.D., Michael Stillabower, M.D., and James Lenhard, M.D.

Description
This study is comparing ZOCOR, a popular cholesterol medication, when taken alone or in combination with extended release niacin to lower the occurrence of heart attacks and stroke. Niacin has the ability to raise good cholesterol (HDL-C) and also may improve total cholesterol by reducing bad cholesterol (LDL-C) and triglycerides. Niacin also exhibits antioxidant, anti-inflammatory and other beneficial effects that could slow the processes that lead to blocked arteries that can cause heart attacks or strokes.


Study title
PLATO Study: Testing a new drug to stop dangerous blood clots

Principle investigator
Andrew Doorey, M.D.

Co-investigators
James Hopkins, M.D., Gilbert Leidig, M.D., and Michael Stillabower, M.D.

Description
Patients who have had a heart attack or who experience very severe chest pain are at high risk for forming blood clots and are often prescribed blood thinners such as clopidogrel (PLAVIX). This study is being carried out to see if an investigational medicine, called AZD6140, works as well or better than PLAVIX in stopping the formation of new blood clots.